AVTX

Avalo Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↑ 7/10
  • Value↓ 0/10
Avalo Therapeutics sales and earnings growth
AVTX Growth
Good
  • Revenue Y/Y↓ -93.73%
  • EPS Y/Y↓ -36.16%
  • FCF Y/Y↓ -14.11%
Avalo Therapeutics gross and profit margin trends
AVTX Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -143627.10%
  • ROIC 5Y↓ 399.38%
Avalo Therapeutics net debt vs free cash flow
AVTX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Avalo Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks